Drugs / Tumor antigen-sensitized DC vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06545630 | Nov 2023 → Nov 2025 overdue | carcinoma, colorectal cancer | West China Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05235607 | Mar 2022 → Jun 2023 | carcinoma, colorectal cancer, melanoma, urinary bladder cancer | Sichuan University | Unknown | No outcome recorded |
| Phase 1 | NCT05023928 | Sep 2021 → Oct 2023 | carcinoma, esophageal cancer | Sichuan University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor antigen-sensitized DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05235607 ↗ |
| Modality | Vaccine | “Tumor antigen-sensitized DC vaccine” NCT05023928 ↗ |
| Route | Subcutaneous | “subcutaneous administration” NCT05235607 ↗ |